Expert Insights on Novel NMOSD Treatments : Episode 2
Treatments With Higher Efficacy and Relapses in NMOSD
This discussion examines how disability accumulation may be influenced by the use of less efficacious treatments, compares the efficacy of novel and traditional NMOSD agents in clinical practice, and reviews relapse rates associated with FDA-approved treatments versus off-label and older therapies.
Video content above is prompted by the following:
- To what extent can disability accumulation be attributed to the use of less efficacious treatments?
- Discuss the use of more efficacious (and novel) and less efficacious (and traditional) neuromyelitis optica spectrum disorder agents in clinical practice.
- What do we know about relapse rates with FDA-approved treatments (eculizumab, satralizumab, inebilizumab, ravulizumab) and off label and older treatments (azathioprine, mycophenolate, and rituximab)?
Recent Videos
Related Content
